NVO

Novo Nordisk regains competitive ground in obesity with the strong launch of the Wegovy pill, reversing some of the recent underperformance against Eli Lilly. NVO's Wegovy pill outpaces Eli Lilly's Foundayo in new-to-brand prescriptions, driven by superior weight loss efficacy and fewer drug interaction restrictions. Despite setbacks, NVO is advancing late-stage candidates like CagriSema, UBT251, and zenagamtide, aiming to rival Eli Lilly's next-generation assets by the early 2030s.

The GLP-1 trade has matured from a single-stock story into a tiered opportunity set.

Novo Nordisk remains a Buy, supported by favorable catalysts and a resilient long-term bull case. NVO has surged 41% since my previous coverage, outperforming the benchmark's 18% return. Despite a recent revenue decline and a 28% drawdown from highs, I believe much of the risk is already priced in.

Danish drugmaker Novo Nordisk launched its weekly basal insulin injection, Awiqli, in India on Thursday, where diabetes rates are among ​the highest in the world.

Shares in Novo Nordisk (NYSE:NVO) fell 2.5% to DKK319.20 after Deutsche Bank pointed to a continued slowdown in the oral version of the company's Wegovy weight-loss drug in the US. The bank published its weekly tracker of prescription data for Novo's GLP-1 franchise, the class of appetite-suppressing treatments that has driven the company's growth.

UBS has reiterated its overweight stance on European pharmaceuticals, framing the sector as a more resilient home for capital than artificial intelligence at a point when the wider market is slowing. The bank argued that the investment case now rests on more than defensive quality.

Healthcare has become Wall Street's bargain bin in 2026, and value hunters are starting to pay attention.

NVO benefits from Medicare's GLP-1 Bridge, but equal coverage for rival therapies shifts the obesity race toward clinical differentiation and long-term outcomes.

Medicare's new GLP-1 coverage could expand access to weight-loss drugs, making ETFs a diversified way to tap growth across the obesity treatment market.

Starting Wednesday, eligible seniors with Medicare coverage can access GLP-1s for obesity with a copay of just $50 per month through a temporary program called Bridge. The move could unlock a vast new patient population for Novo Nordisk and Eli Lilly and dramatically expand access to medications that were previously out of reach for many older Americans.